Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
QuintilesIMS
Cerilliant
Express Scripts
Daiichi Sankyo
McKinsey
Harvard Business School
Fuji

Generated: January 22, 2019

DrugPatentWatch Database Preview

UPTRAVI Drug Profile

« Back to Dashboard

When do Uptravi patents expire, and when can generic versions of Uptravi launch?

Uptravi is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this drug.

This drug has eighty-three patent family members in twenty-eight countries.

The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selexipag profile page.

Summary for UPTRAVI
Drug patent expirations by year for UPTRAVI
Generic Entry Opportunity Date for UPTRAVI
Generic Entry Date for UPTRAVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for UPTRAVI
Synonyms for UPTRAVI
144383-EP2289518A1
144383-EP2292231A1
2-?[4-?[(5,?6-?DIPHENYLPYRAZINYL)(1-?METHYLETHYL)AMINO]BUTOXY]-?N-?(METHYLSULFONYL)-?ACETAMIDE
2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide
2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide
2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide
2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide
2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
3938AH
475086-01-2
5EXC0E384L
ACT 293987
ACT-293987
ACT293987
AK298890
AKOS024457572
B7378
CHEBI:90844
CHEMBL238804
CS-3774
CTK8F0123
D09994
D0N2SR
DB11362
GTPL7552
HE092855
HY-14870
IN2104
KB-79567
KS-00000L89
MFCD10567093
MolPort-009-019-323
NS 304
NS-304
NS-304(Selexipag)
QXWZQTURMXZVHJ-UHFFFAOYSA-N
RT-014761
SCHEMBL674122
Selexipag
Selexipag (JAN/USAN/INN)
Selexipag [USAN:INN]
UNII-5EXC0E384L
Uptravi (TN)
ZINC3990451

US Patents and Regulatory Information for UPTRAVI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for UPTRAVI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000077 Germany ➤ Sign Up PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
2016 00048 Denmark ➤ Sign Up PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
C0042 France ➤ Sign Up PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519
0836 Netherlands ➤ Sign Up PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
16/047 Ireland ➤ Sign Up PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512
266 Luxembourg ➤ Sign Up PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
90044-1 Sweden ➤ Sign Up PRODUCT NAME: SELEXIPAG OR SALT THEROF; REG. NO/DATE: EU/1/15/1083 20160519
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Julphar
Cipla
US Army
UBS
Farmers Insurance
Healthtrust
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.